TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

TEVA$42.61+2.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated statements of changes in equity

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at June 30, 2025	1,253	58	28,003	(14,676)	(2,431)	(4,128)	6,827	7	6,834
Net Income (loss)				433			433	1	434
Other comprehensive income (loss)					(44)		(44)		(44)
Stock-based compensation expense			34				34		34
Dividend to non-controlling interests*								(4)	(4)
Balance at September 30, 2025	1,253	$58	$28,038	$(14,243)	$(2,475)	$(4,128)	$7,250	$4	$7,254

*	In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2024	1,240	58	27,764	(15,173)	(3,148)	(4,128)	5,373	7	5,380
Net Income (loss)				930			930	1	931
Other comprehensive income (loss)					673		673		673
Issuance of Shares	13	*					*		*
Proceeds from exercise of options			3				3		3
Stock-based compensation expense			106				106		106
Purchase of shares from redeemable non-controlling interests**			165				165		165
Dividend to non-controlling interests***								(4)	(4)
Balance at September 30, 2025	1,253	$58	$28,038	$(14,243)	$(2,475)	$(4,128)	$7,250	$4	$7,254

*	Represents an amount less than $0.5 million.

**	In connection with the sale of Teva’s business venture in Japan. See note 17.

***	In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at June 30, 2024	1,239	58	27,829	(14,519)	(2,881)	(4,128)	6,359	204	6,563
Net Income (loss)				(437)			(437)	47	(390)
Other comprehensive income (loss)					113		113	67	180
Issuance of shares	1	*	*				*		*
Stock-based compensation expense			29				29		29
Balance at September 30, 2024	1,240	$58	$27,860	$(14,956)	$(2,769)	$(4,128)	$6,065	$319	$6,383

*	Represents an amount less than 0.5 million.

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2023	1,227	57	27,807	(13,534)	(2,697)	(4,128)	7,506	620	8,126
Net Income (loss)				(1,422)			(1,422)	(262)	(1,684)
Other comprehensive income (loss)					(69)		(69)	(6)	(75)
Issuance of Shares	13	1	*				1		1
Stock-based compensation expense			89				89		89
Proceeds from exercise of options			7				7		7
Dividend to non-controlling interest **								(18)	(18)
Purchase of shares from non-controlling interests***			(45)		(3)		(48)	(16)	(64)
Balance at September 30, 2024	1,240	$58	$27,860	$(14,956)	$(2,769)	$(4,128)	$6,065	$319	$6,383

*	Represents an amount less than $0.5 million.

**	In connection with dividends to non-controlling interests in Teva’s business venture in Japan.

***	Purchase of shares from non-controlling interests in a Teva’s subsidiary in Switzerland.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.